Annovis Bio CEO to Present at New York Investment Conference Amid Neurodegenerative Disease Research Focus

Annovis Bio Inc. announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York City. The presentation provides Annovis Bio with a significant platform to showcase its research and development progress to the investment community. As a company focused on addressing neurodegeneration in diseases such as Alzheimer's Disease and Parkinson's Disease, this conference appearance represents an important opportunity to communicate the company's strategic direction and therapeutic advancements to investors, analysts, and industry leaders from around the world.

Investor conferences like the H.C. Wainwright Global Investment Conference serve as critical venues for emerging biopharmaceutical companies to gain visibility and attract potential investment. The event features presentations from numerous companies across various sectors, allowing investors to evaluate opportunities and make informed decisions about potential investments in the healthcare and biotechnology space. For Annovis Bio, this presentation timing is particularly significant as neurodegenerative diseases represent a growing global health challenge, with Alzheimer's and Parkinson's affecting millions of patients worldwide. Companies like Annovis Bio are working to develop innovative therapies that could potentially improve patient outcomes and quality of life for those suffering from these debilitating conditions.

The conference presentation offers Annovis Bio the chance to demonstrate its scientific progress and business strategies to potential investors who specialize in the healthcare sector. These events often lead to increased analyst coverage, investor interest, and potential partnerships that can accelerate drug development programs and bring new treatments closer to patients in need. The company's participation in this high-profile New York City event underscores the competitive nature of biotechnology investment and the importance of clear communication between research companies and the financial community that supports their work.

For those interested in following the company's developments, investors can access the latest news and updates relating to ANVS in the company's newsroom at https://ibn.fm/ANVS. Additional details about the company's research and therapeutic approaches are available through their corporate website at https://www.annovisbio.com. The presentation at this major investment conference represents a strategic moment for Annovis Bio to position itself within the competitive landscape of neurodegenerative disease research and development, where successful communication with investors can directly impact a company's ability to advance promising therapies through clinical trials and regulatory processes.